UBX - Unity Biotechnology Non-GAAP EPS of -$1.00

2023-03-15 16:49:11 ET

• Unity Biotechnology press release ( NASDAQ: UBX ): Q4 Non-GAAP EPS of -$1.00.
• Cash, cash equivalents and marketable securities totaled $94.8 million as of December 31, 2022 compared with $90.1 million as of December 31, 2021.
• Operating loss for the twelve months ended December 31, 2022 was $57.6 million compared to $56.7 million for the twelve months ended December 31, 2021.
• Cash used in operations during the year ended December 31, 2022 was $51.0 million compared to $45.1 million for the twelve months ended December 31, 2021.
• Total operating loss for the fourth quarter of 2022 was $13.9 million compared to $9.9 million for the fourth quarter of 2021.
• Cash used in operations during the fourth quarter of 2022 was $10.4 million compared to $5.0 million for the fourth quarter of 2021.

For further details see: